Browse News

Found 101 articles

• Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

  6/29/2022

  Galera Therapeutics, Inc. today announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy (SBRT) in patients with centrally located or large non-small cell lung cancer (NSCLC).

• Galera to Present at Jefferies Healthcare Conference

  6/2/2022

  Galera Therapeutics, Inc. announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. E.T.

• Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

  5/26/2022

  Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

• Galera Announces Plan to Submit Avasopasem NDA by Year End After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of 2022

  5/16/2022

  Galera Therapeutics, Inc. announced its intent to file a New Drug Application for avasopasem manganese for the treatment of radiotherapy-induced severe oral mucositis in patients with locally advanced head and neck cancer with the U.S. Food and Drug Administration by the end of 2022.

• Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

  5/16/2022

  Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the first quarter ended March 31, 2022 and provided recent corporate updates.

• Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis

  5/2/2022

  Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced topline results from the six-week, Phase 2a, open-label, single-arm AESOP trial of avasopasem evaluating its ability to reduce the incidence of severe acute radiation-induced esophagitis in patients with lung cancer receiving concurrent chemoradiotherapy.

• Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

  4/27/2022

  Galera Therapeutics, Inc. announced that clinical data from its Phase 3 ROMAN trial of avasopasem for severe oral mucositis will be presented in an oral presentation at the upcoming 2022 American Society of Clinical Oncology Annual Meeting, taking place June 3-7, 2022 in Chicago, Illinois.

• Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates

  3/10/2022

  Galera Therapeutics, Inc. announced financial results for the fourth quarter and year ended December 31, 2021 and provided recent corporate updates.

• Tarsier Pharma Adds Ocular Immunology Experts to Scientific Advisory Board

  3/1/2022

  Tarsier Pharma has expanded its Scientific Advisory Board (SAB).

• Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts

  1/10/2022

  Soligenix, Inc. today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.

• 

  Movers & Shakers, Jan. 7

  1/7/2022

  With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.

• Galera to Present at H.C. Wainwright BioConnect Conference

  1/6/2022

  Galera Therapeutics, Inc. announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022.

• Context Therapeutics® Strengthens Research & Development Team

  1/5/2022

  Context Therapeutics Inc., a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, announced the appointments of Christopher Beck as SVP of Operations and Mark Fletcher, Ph.D., as VP of R&D.

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

• ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, "Cold" Cancers

  12/14/2021

  ImmunoGenesis announced the appointment of seasoned industry veteran Charles Schweizer , PhD, as Senior Vice President of Clinical Development.

• Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

  12/14/2021

  Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced that corrected results from its Phase 3 ROMAN trial of avasopasem for the treatment of RT-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) achieved statistical significance on the primary endpoint of reduction in the incidence of SOM.

• Innovation Pharmaceuticals Provides Brilacidin Program Update

  11/18/2021

  Innovation Pharmaceuticals, a clinical stage biopharmaceutical company, provided an update on clinical development plans for Brilacidin, the Company's defensin-mimetic drug candidate being evaluated in clinical testing for multiple indications.

• Galera to Present at Two Upcoming Investor Conferences in November 2021

  11/15/2021

  Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at two upcoming investor conferences in November.

• Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

  11/10/2021

  Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced financial results for the third quarter ended September 30, 2021 and provided recent corporate updates.

• 

  Clinical Catch-Up: October 18-22

  10/25/2021

  It was yet another busy week for clinical trial news. Here’s a look.